Stephen Basil Thomas - 07 Aug 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
07 Aug 2025
Net transactions value
$0
Form type
4
Filing time
11 Aug 2025, 16:15:08 UTC
Previous filing
01 Jul 2025
Next filing
17 Feb 2026

Quoteable Key Fact

"Stephen Basil Thomas filed Form 4 for Climb Bio, Inc. (CLYM) on 11 Aug 2025."

Quick Takeaways

  • This page summarizes Stephen Basil Thomas's Form 4 filing for Climb Bio, Inc. (CLYM).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 11 Aug 2025, 16:15.

What Changed

  • Previous filing in this sequence was filed on 01 Jul 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas Stephen Basil Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 11 Aug 2025 0002027962

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Award $0 +100,375 +49% $0.000000 304,657 07 Aug 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 27, 2024, the reporting person was granted restricted stock units ("RSUs") to acquire a total of 100,375 shares of common stock that vested based on the achievement of certain performance-based milestones and subject to continuous service. On August 7, 2025, the milestones were deemed to be achieved, resulting in the vesting of the RSUs as to all 100,375 shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .